← Leaderboards
John M Gerdes
Central Washington University
$4,438,779
Attributed
$10,576,093
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,576,093 · 11
By mechanism
U01$3,854,000 · 1
R01$3,230,250 · 1
R21$1,414,971 · 2
R33$1,123,728 · 1
P20$582,124 · 4
R41$225,000 · 1
Top collaborators
- Henry F. Vanbrocklin12 shared
- Kurt R Zinn8 shared
- Charles Thompson7 shared
- David M Wilson4 shared
- Robert Michael Kessler3 shared
- Susanna Rosi1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposLabelTracerPositron-Emission TomographyImageBaseTissuesProtocols DocumentationPositronInvestigationRadioligandPeripheralPrimatesFluorineReportingStructureDesignCerebrumInsightAgingEvaluationBrainRadiotracerMacaca Mulatta
Grant awards (24)
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$804,521
R01 · FY2025 · AG
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$824,846
R01 · FY2024 · AG
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$816,825
R01 · FY2023 · AG
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$784,058
R01 · FY2022 · AG
Molecular Imaging of Chemical Threats and Countermeasures$802,585
U01 · FY2019 · NS
Nonhuman Primate CNS Assessments of 18F-Insulin After IntranasalAdministration$125,813
R21 · FY2019 · AG
Molecular Imaging of Chemical Threats and Countermeasures$804,973
U01 · FY2018 · NS
Nonhuman Primate CNS Assessments of 18F-Insulin After IntranasalAdministration$277,605
R21 · FY2018 · AG
Astroglial EAAT2 Changes in Live TBI Brain Determined by PET Imaging$225,000
R41 · FY2018 · NS
Molecular Imaging of Chemical Threats and Countermeasures$799,473
U01 · FY2017 · NS
Nonhuman Primate CNS Assessments of 18F-Insulin After Intranasal Administration$316,613
R21 · FY2017 · AG
Molecular Imaging of Chemical Threats and Countermeasures$717,099
U01 · FY2016 · NS
Molecular Imaging of Chemical Threats and Countermeasures$729,870
U01 · FY2015 · NS
In Vivo Pharmacokinetic and Pharmacodynamic Dispositions of Positron Radiolabeled$340,256
R21 · FY2011 · NS
PET Imaging Tracers to Quantify Norepinephrine Transporter in the Brain$578,985
R33 · FY2010 · MH · contact PI
In Vivo Pharmacokinetic and Pharmacodynamic Dispositions of Positron Radiolabeled$354,684
R21 · FY2010 · NS
PET Imaging Tracers to Quantify Norepinephrine Transporter in the Brain$544,743
R33 · FY2009 · MH · contact PI
MT COBRE: MAPPING SEROTONIN TRANSPORTER BINDING DOMAINS$145,937
P20 · FY2008 · RR · contact PI
MT COBRE: MAPPING SEROTONIN TRANSPORTER BINDING DOMAINS$158,807
P20 · FY2007 · RR · contact PI
MT COBRE: MAPPING SEROTONIN TRANSPORTER BINDING DOMAINS$156,642
P20 · FY2006 · RR · contact PI
MT COBRE: CHARACTERISTICS OF SEROTONIN TRANSPORTER BINDING DOMAINS$101,686
P20 · FY2005 · RR
CHARACTERISTICS OF SEROTONIN TRANSPORTER BINDING DOMAINS$19,052
P20 · FY2004 · RR
NEW SEROTONIN TRANSPORTER IMAGING AGENTS BY DESIGN$83,697
R15 · FY2000 · NS
NEW SEROTONIN TRANSPORTER IMAGING AGENTS BY DESIGN$62,323
R15 · FY2000 · NS